With the GKV-Beitragssatzstabilisierungsgesetz (Health Insurance Contribution Stabilization Act), cannabis patients are losing flower access through public insurance. What elevates this beyond a simple coverage question is an uncomfortable query: Who profits from the law’s specific design? Surrounding the rushed tightening are names, donations, and an explicit product recommendation that have critics raising eyebrows. We break down what’s proven and what remains unsubstantiated.
📑 Inhaltsverzeichnis
What’s at Stake
To set the record straight: dried cannabis flowers are being completely excluded from statutory health insurance reimbursement (§ 31 Section 6 SGB V). Cannabis-containing compounded medications like extracts are additionally barred from coverage during the first six months of treatment, only becoming reimbursable after failed treatment attempts with an approved finished pharmaceutical product. Approximately 65,000 insured patients are affected. We’ve detailed the decision’s specifics in our report on the Bundestag’s removal of flowers from insurance coverage. This article explores a different dimension: the economic and political interests at play.
One Entrepreneur, One Medication, Four Party Donations
At the center of scrutiny is Munich-based Vertanical and its founder and shareholder Clemens Fischer, who simultaneously chairs the supervisory board of publicly traded pharmaceutical company PharmaSGP. Vertanical brought Exilby, a cannabis-containing finished pharmaceutical product for chronic back pain, to market. This very approval is significant because insured patients starting therapy now have access to only a handful of THC-containing finished medications—primarily Sativex and Exilby.
This intensifies the situation for the largest patient group. Of the four cannabis-containing finished medications approved in Germany, Sativex (spasticity from multiple sclerosis), Epidiolex (certain epilepsy types), and Canemes (nausea from chemotherapy) address narrowly defined conditions. For chronic pain—the affliction affecting most cannabis patients—Exilby is the only specifically approved product. Moving forward, insured patients starting treatment for chronic pain will almost inevitably land on medication from Fischer’s company first. A finished inhalable product for acute pain flare-ups is entirely absent from the list.
Publicly documented are Fischer’s party donations before the 2024 federal election, appearing in political party accounting reports published in 2026. According to Business Insider research, he donated a total of €560,000: €200,000 to the CSU, €200,000 to the FDP, €100,000 to the SPD, and €60,000 to the CDU. Fischer himself justified the payments by saying he wanted to „strengthen the political center.“ The donations were legal and properly disclosed.
The Accusation and Its Limits
The case gained critical weight through developments in the Health Committee. During the hearing on June 22, 2026, the then-chairman of the Joint Federal Committee, Josef Hecken, spoke in favor of tightening in favor of finished pharmaceuticals when questioned by CSU representative Stefan Pilsinger, recommending the six-month exclusion of compounded prescriptions. He specifically named the newly approved product Exilby as a possible alternative. Hecken left office on June 30, 2026, at his own request.
The German Hemp Association views this as a scandal. Executive director Georg Wurth uses stark language: „It looks very much like someone bought a monopoly for their product with the political parties for half a million euros, at the expense of the insured.“ The association demands comprehensive political investigation.
This interpretation represents the association’s assessment, not a proven fact. Even the Hemp Association itself acknowledges that no publicly documented evidence yet exists for a causal connection between the donations and the legislative change. The individual pieces are documented: the donations, the timing relative to the election, and the named product recommendation in committee. Whether these constitute an actual conflict of interest remains unproven. It remains a substantiated initial suspicion that warrants clarification by policymakers and the public.
Fischer’s Perspective
For fairness, the other side deserves hearing. Fischer frames his donations as expressions of political conviction, not investments in specific legislation. He wanted to support centrist parties he believes are necessary for economic and social progress. A substantive argument also supports Exilby: it’s a regularly approved, clinically tested pharmaceutical with standardized active ingredient content, whereas flowers vary more significantly in quality and dosage. Those favoring the shift toward finished pharmaceuticals cite medication safety, reproducible effects, and physician-directed control. Whether this argument justifies the specific design with the six-month compounding exclusion remains disputed.
There’s also an open question about costs: no reimbursement price negotiated with health insurers has been set for Exilby yet. In the first six months after market introduction, the company sets the price itself; negotiations with the GKV bargaining association only follow. It’s precisely during this phase that patients are supposed to switch to this product.
The Industry: Savings That Aren’t
Independently of the donation question, industry organizations criticize the law’s economic logic. The Cannabis Industry Association calls the claimed savings potential „methodologically unreliable“ and warns of cost-shifting, therapy interruptions, and new risks harming patients and ultimately the healthcare system itself. The association recommends completely striking the amendment to § 31 Section 6 SGB V and instead comprehensively evaluating actual care provision. A broad coalition of associations argues similarly, pointing to coverage cuts without commensurate savings. Opposition also comes from pharmacies and medical organizations, citing compromised physician therapy autonomy among other concerns.
The core economic objection: if patients switch from comparatively inexpensive flowers and compounded products to pricier finished pharmaceuticals whose introductory-phase prices the company itself sets, it’s unclear whether actual savings occur. Critics anticipate displacement: patients unable to find adequate reimbursable therapy will shift to out-of-pocket payment, potentially toward illegal markets or alternative substances. Economically, this could generate higher costs elsewhere than the law saves on cannabis flower spending.
What Comes Next
Several associations had urged the Bundesrat to invoke the mediation committee and force improvements. This didn’t happen: the upper chamber allowed the savings law to pass without triggering mediation proceedings. The new regulation stands. Political debate over later corrections, handling of conflicts of interest, and actual costs will likely continue nonetheless.
Conclusion
The situation leaves an uneasy feeling and raises legitimate questions. What’s documented: substantial party donations from an entrepreneur whose product benefits from the adopted regulation, plus a named product recommendation in the decisive committee. What’s not documented: a causal connection between the two. This distinction isn’t trivial—it’s central to rigorous analysis. For the 65,000 affected patients, it changes nothing about their reality: their existing therapy hangs in the balance while the question of who benefits remains unanswered.
Sollten Cannabisblüten weiterhin auf Kassenrezept erstattbar sein?
Sources: Business Insider (report on Clemens Fischer’s party donations, €560,000), German Hemp Association (press release, July 10, 2026), Cannabis Industry Association, Association of Cannabis-Supplying Pharmacies, Pharmaceutical Times, German Pharmacy News, party financial disclosures.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
